Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover

Bone

Volumn 20, Issue 1, 1997, Pages 63-67

  Schlemmer, A ^a   Ravn, P ^a   Hassager, C ^a   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Bone resorption; Circadian rhythm; Nasal calcitonin

Indexed keywords

BIOCHEMICAL MARKER; OSTEOCALCIN; SALCATONIN;

ADULT; AGED; ARTICLE; BONE TURNOVER; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; OSTEOLYSIS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ANALGESICS; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CALCITONIN; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; OSTEOCALCIN; RADIOIMMUNOASSAY;

EID: 0031012503     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(96)00307-9     Document Type: Article

References (34)

1. Alexandersen, P., Schlemmer, A., Riis, B. J., and Christiansen, C. Circadian Variation in crosslaps - a new marker of bone resorption [Abstract A218]. J Bone Miner Res 9(Suppl. 1):S190; 1994.
2. Blumsohn, A., Herrington, K., Hannon, R. A., Shao, P., Eyre, D. R., and Eastell, R. The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab 79:730-735; 1994.
3. Bonde, M., Qvist, P., Fledelius, C., Riis, B. J., and Christiansen, C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022-2025; 1994.
4. Bonde, M., Qvist, P., Fledelius, C., Riis, B. J., and Christiansen, C. Applications of an enzyme immunoassay for a new marker of bone resorption (Cross-Laps): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864-868; 1995.
5. Civitelle, R., Gonnelli, S., Zacchei, F., Bigacci, S., Vattimo, A., Avioli, L. C., and Gennari, C. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268-1274; 1988.
6. Eastell, R., Calvo, M. S., Burritt, M. F., Offord, K. P., Russell, R. G. G., and Riggs, B. L. Abnormalities in circadian patterns of bone resorption an renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab 74:487-494; 1992.
7. Eastell, R., Simmons, P. S., Colwell, A., Assiri, A. M. A., Burritt, M. F., Russell, R. G. G., and Riggs, B. L. Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: Effects of growth and aging. Clin Sci 83:375-382; 1992.
8. Fioretti, P., Gambacciani, M., Taponeco, F., Melis, G. B., Capelli, N., and Spinetti, A. Effect of continuous and cyclical nasal calcitonin administration in ovariectomized women. Maturitas 15:225-232; 1992.
9. Garnero, P., Gineyts, E., Riou, J. P., and Delmas, P. D. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785; 1994.
10. Hosking, D. J. Treatment of severe hypercalcemia with calcitonin. Metab Bone Dis Rel Res 2:207-212; 1980.
11. Kanis, J. A., Horn, D. B., Scott, R. D. M., and Strong, J. A. Treatment of Paget's disease of bone with synthetic salmon calcitonin. BMJ 3:727-731; 1974.
12. Ledger, G. A., Burkitt, M. F., Kao, P. C., O'Fallon, W. M., Riggs, B. L., and Khosla, S. Role of parathyroid hormone in mediating nocturnal and age-related increase in bone resorption. J Clin Endocrinol Metab 80:3304-3310; 1995.
13. Matthews, J. N. S., Altman, D. G., Campbell, M. J., and Royston, P. Analysis of serial measurements in medical research. Br Med J 300:230-235; 1990.
14. Milhaud, G. and Job, J.-C. Thyrocalcitonin: Effect on idiopathic hypercalcemia. Science 154:794-796; 1966.
15. Nelson, W., Tong, Y. L., Lee, J.-K., and Halberg, F. Methods for cosinor rhythmometry. Chronobiologia 6:305-323; 1979.
16. Nielsen, H. K. Circadian and circatrigentan changes in osteoblastic activity assessed by serum osteocalcin. Physiological and methodological aspects. Dan Med Bull 41:216-217; 1994.
17. Overgaard, K. Nasal salmon calcitonin in osteoporosis [editorial]. Calcif Tissue Int 55:79-81; 1994.
18. Overgaard, K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study. Calcif Tissue Int 55:82-86; 1994.
19. Overgaard, K., Hansen, M. A., Jensen, S. B., and Christiansen, C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. Br Med J 305:556-561; 1992.
20. Overgaard, K., Riis, B. J., Christiansen, C., and Hansen, M. A. Effect of salcatonin given intranasally on early postmenopausal bone loss. Br Med J 299:477-449; 1989.
21. Overgaard, K., Riis, B. J., Christiansen, C., Pødenphant, J., and Johansen, J. S. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435-442; 1989.
22. Pedersen, B. J., Schlemmer, A., Hassager, C., and Christiansen, C. Changes in the carboxy-terminal propeptide of type I procollagen and other markers of bone formation upon five days of bed rest. Bone 17:91-95; 1995.
23. Reginster, J. Y., Denis, P., Deroisy, R., Lecart, M. P., de Longuevill, M., Zegels, B., Sarlet, N., Noirfalisse, P., and Franchimont, P. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 9:69-73; 1994.
24. Reginster, J. Y., Meurmans, L., Deroisy, R., Jupsin, I., Biquet, I., Albert, A., and Franchimont, P. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 24:565-569; 1994.
25. Reynolds, J. J. and Dingle, J. T. A sensitive in vitro method for studying the induction and inhibition of bone resorption. Calcif Tissue Res 4:339-349; 1970.
26. Sairanen, S., Tahtela, R., Laitinen, K., Karonen, S. L., and Valimaki, M. J. Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin. Calcif Tissue Int 55:349-352; 1994.
27. SAS Institute. SAS/STAT guide for personal computers, 6th ed. Cary, NC: SAS Institute; 1987.
28. Schlemmer, A., Hassager, C., Alexandersen, P., Fledelius, C., Østergaard, L., and Christiansen, C. The circadian variation in bone resorption is not related to serum cortisol [Abstract S357]. J Bone Miner Res 10(Suppl. 1): S240; 1995.
29. Schlemmer, A., Hassager, C., Jensen, S. B., and Christiansen, C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 74:476-480; 1992.
30. Schlemmer, A., Hassager, C., Pedersen, B. J., and Christiansen, C. Posture, age, menopause and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium cross-links. J Bone Miner Res 9:1883-1888; 1994.
31. Thamsborg, G., Skousgaard, S.G., Daugaard, H., Schifter, S., Kollerup, G., and Sørensen, O. H. Acute effect of nasal salmon calcitonin on calcium and bone metabolism. Calcif Tissue Int 53:232-236; 1993.
32. Thamsborg, G., Storm, T. L., Sykuski, R., Brinch, E., Nielsen, H. K., and Sørensen, O. H. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 48:302-307; 1991.
33. van der Wiel, H. E., Lips, P., Nauta, J., Kwakkel, G., Hazenberg, H., Netelenbos, J.C., van der Vijgh, W. J. F. Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: A double-blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover. J Bone Miner Res 8:1459-1465; 1993.
34. Woodhouse, N. J. Y., Bordier, P. H., Fisher, M., Joplin, G. F., Reiner, M., Kalu, D. N., Foster, G. V., and MacIntyre, I. Human calcitonin in the treatment of Paget's bone disease. Lancet i: 1139-1143; 1971.